Allison Ambrose Sells Shares of Upstream Bio, Inc. $UPB

Written by Podchat · Published · Updated

Key Points

  • Allison Ambrose sold 477 shares of Upstream Bio, Inc. ($UPB) worth $2,909.70.
  • $UPB last traded around $6.23.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Allison Ambrose, General Counsel at Upstream Bio, Inc. ($UPB), sold 477 shares at an average price of $6.10, for a total transaction of $2,909.70. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Upstream Bio, Inc. Stock Down 6.9%

Shares of Upstream Bio, Inc. ($UPB) traded around $6.23 on Wednesday, down 6.9% for the day.

Last price$6.23
Market cap$362.58M
Forward P/E-2.26
52-week low$5.85
52-week high$33.68
50-day MA$6.92
200-day MA$14.34
Current ratio27.99
Quick ratio26.38
Debt-to-equity0

Upstream Bio, Inc. Earnings

EPS (ttm)-$2.85
Revenue (ttm)$3.16M
Revenue growth-17.50%
Net margin0%
Return on equity-46.05%
Next earningsNov 4, 2026

Analysts Set New Price Targets

Average target$33.50
High target$75
Low target$9
Analysts covering8

About Upstream Bio, Inc.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

ExchangeNasdaqGS
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
CEODr. E. Rand Sutherland M.D., M.P.H.
Employees75
Websitehttps://upstreambio.com

Get Upstream Bio, Inc. alerts

New 13F filings, insider trades, and analyst moves on $UPB, sent to your inbox. Free, and you can unsubscribe anytime.

Related Filing Alerts

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.